R
Renee A. Desmond
Researcher at University of Alabama at Birmingham
Publications - Â 185
Citations - Â 11940
Renee A. Desmond is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: Cancer & Population. The author has an hindex of 58, co-authored 185 publications receiving 11232 citations. Previous affiliations of Renee A. Desmond include American Society of Clinical Oncology & Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model.
Akseli Hemminki,Anna Kanerva,Eric J. Kremer,Gerd J. Bauerschmitz,Bruce F. Smith,Bin Liu,Minghui Wang,Renee A. Desmond,Anne Keriel,Brian G. Barnett,Henry J. Baker,Gene P. Siegal,David T. Curiel +12 more
TL;DR: This work generated and tested the first nonhuman oncolytic adenovirus that effectively killed canine osteosarcoma cells in vitro and yielded a therapeutic benefit in vivo, and suggested immunomodulation for increased on colytic potency could be studied with clinical trials in this population.
Journal ArticleDOI
A Randomized Trial of the Duration of Therapy with Metronidazole plus or minus Azithromycin for Treatment of Symptomatic Bacterial Vaginosis
TL;DR: Cure rates for BV were significantly improved by 14 days of metronidazole treatment (compared with 7 days of treatment), but the effects were not sustained, suggesting that relapse or reinfection occurred.
Journal ArticleDOI
A randomized trial of metronidazole in asymptomatic bacterial vaginosis to prevent the acquisition of sexually transmitted diseases.
TL;DR: Treatment and twice-weekly prophylactic use of intravaginal metronidazole gel resulted in significantly fewer cases of chlamydia.
Journal ArticleDOI
Light-intensity activity attenuates functional decline in older cancer survivors.
Cindy K. Blair,Miriam C. Morey,Renee A. Desmond,Harvey J. Cohen,Richard Sloane,Denise C. Snyder,Wendy Demark-Wahnefried,Wendy Demark-Wahnefried +7 more
TL;DR: It is suggested that increasing light- intensity activities, especially HLPA, may be a viable approach to reducing the rate of physical function decline in individuals who are unable or reluctant to initiate or maintain adequate levels of moderate-intensity activities.
Journal ArticleDOI
Locoregionally Advanced Head and Neck Cancer Treated With Primary Radiotherapy: A Comparison of the Addition of Cetuximab or Chemotherapy and the Impact of Protocol Treatment
Jimmy J. Caudell,Stephen M. Sawrie,Sharon A. Spencer,Renee A. Desmond,William R. Carroll,Glenn E. Peters,Lisle Nabell,Ruby F. Meredith,James A. Bonner +8 more
TL;DR: A single-institution retrospective review of patients treated with ExRT or ChRT for locoregional control, distant metastasis-free survival, disease-specific survival, and overall survival found no significant differences.